Axis Therapeutics enters into a research collaboration with PharmaEssentia
Axis Therapeutics has entered into a research collaboration with PharmaEssentia Corporation to develop the T Cell Receptor (TCR)-T therapy based on the proprietary TAEST (T cell receptor Affinity Enhancing Specific T cell therapy) technology platform based in Taiwan.
Under the agreement, Axis Therapeutics and PharmaEssentia will be collaborating in conducting an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients, and to manufacture the investigational product in Taiwan. PharmaEssentia will be in charge of all the clinical development activities in Taiwan.
Both companies, in separate statements, expressed their excitement to work with one another in advancing the TCR-T therapy.
Dyno and Roche partners to tackle CNS, liver disease using gene therapy
Dyno recently announced its next partnership with Roche and its Spark Therapeutics unit to develop the central nervous system (CNS) and liver-directed gene therapies recently.
Although no financial details were revealed, the deal was said to potentially exceed $1.8 billion in clinical and sales milestones.
According to Dyno’s Chief Executive Officer, Eric Kelsic, Gene therapies are one of the most popular areas of investment in the biotech world today along with artificial-intelligence-assisted research methodologies, of which both are covered by Dyno.
Dyno is currently working on CNS and liver disorders with Roche, eye disorders with Novartis, and muscle disorders with Sarepta Therapeutics.
MilliporeSigma launches it Lentiviral Production Platform, VirusExpress
MilliporeSigma has launched the VirusExpress™ lentiviral production platform, helping to overcome lentiviral production challenges and reduce process development timelines by approximately 40%.
The platform uses a suspension cell line rather than an adherent-based production, coupled with a chemically defined cell culture media and process with built-in scalability. It is said to meet multiple market needs by accelerating process development, simplifying upstream workflow, and allowing more doses to be manufactured.
This new offering highlights MilliporeSigma’s continued investment in cell and gene therapies after a $110 million investment on a new site in California, United States back in April.